ECE2013 Poster Presentations Diabetes (151 abstracts)
Insulin detemir has similar effect when using single daily dose with same dose twice daily as basal insulin therapy with oral antidiabetics.
Soner Cander 1, , Oguzhan Sitki Dizdar 3 , Ozen Oz Gul 2, , Aysen Akkurt 2 , Metin Guclu 4 , Oguz Kaan Unal 5 , Ercan Tuncel 2 , Erdinc Erturk 2 , Sazi Imamoglu 2 & Canan Ersoy 2
1Bursa Sevket Yilmaz Education and Research Hospital, Endocrinology and Metabolism, Bursa, Turkey; 2Uludag University Medical School, Endocrinology and Metabolism, Bursa, Turkey; 3Uludag University Medical School, Internal Medicine, Bursa, Turkey; 4Bursa Cekirge State Hospital, Endocrinology and Metabolism, Bursa, Turkey; 5Aksaray State Hospital, Bursa, Turkey.
Aim: To compare the effectiveness of insulin detemir when added to oral antidiabetic drug therapy as a single daily dose or twice daily.
Method: Fifty patients with a diagnosis of type 2 diabetes receiving oral antidiabetic drug therapy and glycemic control did not provided were included the study. Insulin detemir was begun 0.1–0.2 U/kg daily dose, half of the patients started with a single daily dose and the other half with same dose twice daily. At the end of the twelfth week, the groups were crossing. Insulin doses was titrated every 2 weeks for 24 weeks according to capillary blood glucose including in the morning and in the evening levels.
Results: Fifty patients completed the study, mean age was 55.5 years (M/F: 26/24), mean duration of diabetes was 7.0 years and initial HbA1c mean was 9.5%±1.2. Initial mean HbA1c was 9.8%±1.3 in the group receiving single dose (Group I), and was 1.5±9.3% in the double-dose group (Group II). At the end of 12 weeks, improvements in HbA1c levels were observed 1.8% in Group I and 1.5% in Group II (P=0.6). Change in A1c levels in the next 12 weeks after cross-over, were −0.2% and −0.1% in Group 1 and Group 2 (P=0.6). While the initial daily insulin doses were 0.11/kg in both groups, at the end of the first twelve weeks it was 0.29 in the Group I, and 0.32 in the Group II (P=0.2). After crossover, daily insulin doses were 0.42 and 0.38 (P=0.3) respectively. Daily insulin dose was only about 10% higher in double-dose periods and was not statistically significant in pre and post crossover periods.
Conclusion: Reason for the difference in dose requirement may be due to comfortable and easily titration ability feature of double daily dose. According to the results obtained in this study, a single daily dose of insulin detemir has a similar effect at the same dose of twice daily when used as basal therapy with oral antidiabetics.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more